Overview

6MW3511 in Patients With Advanced Solid Tumor

Status:
Not yet recruiting

Trial end date:
2024-09-01

Target enrollment:

Participant gender:

Summary

This is a phase I/II , open-label, multicenter single arm study designed to evaluate the safety, tolerability, pharmacokinetic (PK), and immunogenicity of 6MW3511.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Mabwell (Shanghai) Bioscience Co., Ltd.